Uveitis as a Result of MAP Kinase Pathway Inhibition

We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previou...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Lavnish, Karydis, Andreas, Gemenetzi, Maria, Shao, Emily H., Taylor, Simon R.J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: November, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901607/
https://www.ncbi.nlm.nih.gov/pubmed/24474928
http://dx.doi.org/10.1159/000357060
Descripción
Sumario:We report the case of a patient treated with dabrafenib and trametinib (mitogen-activated protein kinase pathway inhibitors) for stage 3b cutaneous melanoma who developed bilateral uveitis. Although there have been reports of ocular side effects with this class of drugs, uveitis has not been previously reported to the best of our knowledge. This case indicates the wide range of side effects that can be seen with the newer targeted biological therapies.

Ejemplares similares